Search

Displaying results 9411 - 9420 of 10000 in total
  1. Drug

    DNB-001

    go.drugbank.com/drugs/DB05757
    Investigational

    DNB-001 is a first-in-class oral therapy with dual mechanism of action, which is initially being developed for the treatment of glaucoma.

  2. Drug

    Alkaline Phosphatase

    go.drugbank.com/drugs/DB05768
    Investigational

    Alkaline Phosphatase (AP) is an oral treatment and has a very favorable side-effect profile.

  3. Drug

    Arylacenamide

    go.drugbank.com/drugs/DB05792
    Experimental

    It is a dual agent with both immunomodulatory and antiproliferative activities. … Arylacenamide (SR31747) is a peripheral [sigma] ligand that binds four proteins in human cells, i.e. SRBP-1, [sigma]-2, HSI and its relative SRBP-2.

  4. Drug

    PRO-542

    go.drugbank.com/drugs/DB05793
    Investigational

    PRO 542 belongs to a new class of drugs, viral-entry inhibitor, which is intended to prevent HIV from entering and infecting cells. … PRO 542 (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutralizes primary HIV-1 isolates.

  5. Drug

    Daglutril

    go.drugbank.com/drugs/DB05796
    Investigational

    Daglutril is an orally active, mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development for the treatment of essential hypertension and congestive heart failure.

  6. Drug

    ISIS 14803

    go.drugbank.com/drugs/DB05803
    Investigational

    ISIS 14803 is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits

  7. Drug

    NS-2359

    go.drugbank.com/drugs/DB05805
    Investigational

    NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression. … Enhancing the function of the three neurotransmitters serotonin, noradrenalin and dopamine, NS2359 has a desired "triple-mode-of-action".

  8. Drug

    CNS-5161

    go.drugbank.com/drugs/DB05824
    Experimental

    CNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.

  9. Drug

    ING-1

    go.drugbank.com/drugs/DB05831
    Investigational

    ING-1 is a high-affinity, human engineered trade mark monoclonal antibody that recognizes a 40 kilodalton epithelial cell adhesion molecule (EpCAM) glycoprotein that is expressed in high levels on most

  10. Drug

    PPI-1019

    go.drugbank.com/drugs/DB05832
    Investigational

    Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.